Concerto Biosciences
PrivateLast Round
Series A
Nov 2, 2022
Total Funding Raised
$23.6M
Company Overview
Concerto Biosciences operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in November 2022.
Concerto Biosciences is a biotechnology company that develops microbe-based products by measuring and mapping microbial interactions to address needs in skin health, women's health, and food science.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Concerto Biosciences Comparables
Compare Concerto Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pluton Biosciences | 84% | |
| Microbiotica | 77% | |
| Kanvas Biosciences | 69% |
For institutional investors. Book with your work email.
Concerto Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 2, 2022 | ||||
| Grant | Sep 1, 2022 | ||||
| Grant | Jul 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Concerto Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Horizons Ventures | Series A |
| National Institute of Allergy and Infectious Diseases | Grant |
| Engine Ventures | Seed |
| M Ventures | Series A |
| MassVentures | Series A |
| Impact Science Ventures | Series A |
| Safar Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 30, 2026
Partnered with Sacco System for development and commercialisation.
- Jan 29, 2025
Stewart Campbell appointed as Independent Director.
For institutional investors. Book with your work email.
Concerto Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Concerto Biosciences's valuation, stock price, and market status.
Is Concerto Biosciences a public or private company?
Concerto Biosciences is a private company.
What is the current stock price of Concerto Biosciences?
Concerto Biosciences is a private company, so its shares have no public market price. Caplight tracks Concerto Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Concerto Biosciences worth (valuation)?
Valuation information for Concerto Biosciences is not publicly available.
Can I buy Concerto Biosciences stock?
Concerto Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Concerto Biosciences's last funding round?
Concerto Biosciences's most recent funding round was Series A on November 2, 2022.
Who are the main investors in Concerto Biosciences?
Key investors in Concerto Biosciences include Safar Partners.
Will Concerto Biosciences IPO soon?
No public IPO plans have been announced for Concerto Biosciences.
How can I track Concerto Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Concerto Biosciences's shares on secondary markets.